Cholesterol ManagementJun 4, 2026
A lower dose of a statin paired with ezetimibe can deliver the same cardiovascular protection as cranking the statin dose to maximum, while causing fewer muscle complaints, less diabetes risk, and better long-term adherence. That's the core finding from large randomized trials and meta-analyses comparing these two strategies head to head.
If you've been told you need a statin but worry about tolerability, or if you're already on a high dose and struggling with side effects, this combination approach is worth understanding. The evidence is strong enough that it's reshaping how clinicians think about lipid-lowering therapy, especially for older adults and people prone to statin-related problems.
Prostate CancerJun 4, 2026
Eligard, an injectable form of leuprolide acetate, pushes testosterone down to castrate levels in the vast majority of men with prostate cancer. But "vast majority" ranges from 94% to 98% with shorter dosing intervals, dropping to roughly 88–90% with the longest option. That gap is worth understanding if you or someone you care about is choosing between a shot every month versus every six months.
Eligard works as a GnRH agonist (gonadotropin-releasing hormone agonist), which essentially tricks the brain's hormonal signaling system into shutting down testosterone production. It uses a polymer gel called Atrigel that forms a small biodegradable implant under the skin, slowly releasing leuprolide over weeks or months depending on the formulation.
GLP-1Jun 4, 2026
In the trial that got Zepbound approved, the average person on the highest 15 mg dose lost 20.9% of their body weight over 72 weeks. The 10 mg dose was 19.5%, and the 5 mg dose was 15.0%. The highest dose wins on paper, but only by 1.4 percentage points over 10 mg, while gastrointestinal side effects keep rising and discontinuation creeps up.
If you're thinking about Zepbound, the more useful question isn't which dose produces the absolute most weight loss in a trial. It's which dose produces the most weight loss YOU can actually stay on for a year or longer. Those answers can differ.
GLP-1Jun 4, 2026
In a trial of 27,564 patients followed for over two years, evolocumab (Repatha) cut LDL cholesterol by 59% and lowered major cardiovascular events by 15%, with no meaningful difference in adverse events versus placebo aside from a small uptick in injection-site reactions. Weight loss was not on the list of effects, then or in any subsequent analysis.
If you have heard that an injectable drug helps with weight, you are probably thinking of a different class. Wegovy, Zepbound, Ozempic, and Mounjaro are GLP-1 receptor agonists, designed specifically to drive weight loss. Repatha was designed for cholesterol.
They are all injections, administered weekly or monthly, and all expensive. They do not do the same thing.
Cardiovascular HealthJun 4, 2026
It's an exciting time to be involved in cardiovascular medicine. For years, statins have been the cornerstone of cholesterol management, effectively lowering low-density lipoprotein (LDL) cholesterol levels. However, many individuals still struggle to reach their cholesterol goals through lifestyle changes and statin therapy alone.
That's where PCSK9 inhibitors come into play.
Cardiovascular HealthJun 4, 2026
When it comes to lowering cholesterol, most doctors start with a statin. These medications have been used for decades, are backed by research, and work well for many people. But not everyone responds the same way. Some people see great results, while others experience little improvement. So how do you know which medication will work best for you?
ADHDJun 4, 2026
Vyvanse and Adderall XR are both amphetamine-based stimulants prescribed for ADHD, and both deliver roughly 10 hours of clinical effect. But the way each one gets amphetamine into your system is fundamentally different, and that engineering gap has real consequences for abuse potential, drug interactions, and daily convenience.
The core tension is this: direct head-to-head efficacy trials between these two medications are scarce. No clear winner has been established for symptom control. So the choice between them usually comes down to practical differences in formulation, metabolism, and risk profile rather than one simply "working better" than the other.
Cardiovascular HealthJun 4, 2026
Medications for chronic conditions, such as high cholesterol, often provoke strong opinions. Statins, widely used to lower cholesterol, are hailed as lifesaving by some and vilified by others. But how do you decide whether taking a medication is right for you? Instead of relying on anecdotes or media narratives, we advocate cutting through the noise with a structured, data-driven approach.
Cardiovascular HealthJun 4, 2026
Praluent (alirocumab) can cut LDL cholesterol by roughly 60% in patients already taking the highest tolerated statin dose. That alone is striking. But the more compelling finding is what happens next: in a trial of nearly 19,000 people who had recently suffered a heart attack or acute coronary event, that LDL drop translated into a 15% reduction in major cardiovascular events, including heart attack, stroke, and cardiovascular death. The catch is that not everyone gets the same payoff. Where your LDL starts and whether you have diabetes dramatically change the math.
Praluent is a subcutaneous injection, not a pill. It belongs to a class called PCSK9 inhibitors, and it's approved specifically as an add-on for adults with familial hypercholesterolemia or established cardiovascular disease who need more LDL lowering than statins alone can deliver. This isn't a first-line treatment. It's the next step when statins aren't getting the job done.
GLP-1Jun 4, 2026
Zepbound's pen authorizes three injection sites (abdomen, thigh, and upper arm), and pharmacokinetic data show the drug absorbs about the same regardless of which one you use. The catch is what happens to the skin underneath after weeks of injecting in roughly the same place: a fibrofatty thickening called lipohypertrophy, which affects up to 60% of long-term self-injecting diabetes patients.
If you're holding your first Zepbound pen and wondering which site to use, the answer is: any of the three. The bigger question is what you'll do over the months that follow. Where you keep returning the needle, more than where you start, decides whether the medication still absorbs as expected after dozens of doses.
Irritable Bowel SyndromeJun 4, 2026
Most drugs for irritable bowel syndrome with constipation (IBS-C) get absorbed into your bloodstream and work from the inside out. Ibsrela (tenapanor) takes the opposite approach. It acts almost entirely within the gut itself, with very low absorption into the body. That local-only design is central to both how it works and why its safety profile looks the way it does.
FDA-approved in 2019, Ibsrela at 50 mg twice daily improved both constipation and abdominal pain in trials involving more than 1,200 adults. The trade-off is straightforward: diarrhea is the most common side effect, but it tends to be mild to moderate and shows up early rather than building over time.
Cardiovascular HealthJun 4, 2026
Statins are among the most commonly prescribed medications worldwide for managing cholesterol levels. While their effectiveness in reducing cardiovascular risks is well-established, concerns about potential side effects often deter people from taking them. Here, we'll explore how statins work, assess their benefits, and weigh them against their risks to help you make an informed decision.
GLP-1Jun 4, 2026
In the landmark trial that got Zepbound approved, the average person on the 15 mg dose lost 20.9% of their starting body weight over 72 weeks. That number gets quoted constantly in marketing copy, but it hides three things every prospective patient should know: results depend heavily on dose, real-world losses tend to be smaller, and the weight comes back fast if you stop the drug.
This is what tens of thousands of patients across clinical trials and real-world studies tell us about what to actually expect.
Cardiovascular HealthJun 4, 2026
Statins have been the cornerstone of cholesterol-lowering therapy for decades, primarily because of their proven ability to reduce low-density lipoprotein cholesterol (LDL-C) and lower the risk of cardiovascular events such as heart attacks and strokes. However, not all patients can tolerate statins. Muscle-related side effects, liver enzyme elevations, and even increased risk for developing type 2 diabetes in some individuals have led many to seek alternatives. In fact, studies suggest that up to 20% of patients may discontinue statins due to adverse effects or intolerance.
When patients stop taking statins, either due to side effects or concerns about long-term safety, they often lose the protective cardiovascular benefits statins provide. This has prompted significant interest in both pharmacological and natural alternatives that can effectively manage cholesterol levels without the common drawbacks associated with statins.
Weight LossJun 4, 2026
If you're considering prescription weight loss medication, you've probably heard of Zepbound and Wegovy. Both are weekly injections that produce significant weight loss, but one consistently outperforms the other on the scale. The tradeoff? The drug that helps you lose more weight doesn't yet have the same proof that it'll protect your heart.
Here's the bottom line from clinical trials: Zepbound typically produces about 5-7 percentage points more weight loss than Wegovy over a year to 18 months. But Wegovy has years of rigorous data showing it reduces heart attacks, strokes, and cardiovascular deaths. Zepbound's heart protection data is still being gathered, with major trial results expected soon.
NutrientsJun 4, 2026
If you're taking red yeast rice for cholesterol or considering it as an alternative to statins, you've probably heard that adding CoQ10 (coenzyme Q10) can help prevent the muscle aches and fatigue that sometimes come with these treatments. But does the science actually back this up?
Here's the honest answer: the evidence is mixed, and it depends on your specific situation. Some people do seem to benefit, particularly those with general fatigue on statins. But if you have true muscle pain (myopathy), the most rigorous clinical trials suggest CoQ10 may not be the fix you're hoping for. Let's break down what the research actually shows.
Pain ManagementJun 4, 2026
Pregabalin (brand name Lyrica) generally relieves neuropathic pain more quickly and slightly more effectively than gabapentin across multiple systematic reviews and meta-analyses. But that speed comes at a cost: more central nervous system side effects, a higher potential for misuse, and a bigger price tag per pill. The real question isn't which drug is "better." It's which tradeoff makes sense for your specific situation.
Both drugs are gabapentinoids, meaning they act on similar receptors in the nervous system. They're prescribed for overlapping conditions: postherpetic neuralgia (nerve pain after shingles), diabetic neuropathy, spinal cord injury pain, sciatica, and failed back surgery syndrome. But they are not interchangeable. Their differences in potency, how the body absorbs them, side-effect profiles, and cost create meaningfully different experiences for the people taking them.
Gut HealthJun 4, 2026
If you've ever dealt with constipation, there's a good chance someone recommended docusate sodium. It's one of the most commonly prescribed stool softeners in hospitals and a fixture in drugstore laxative aisles. But here's the uncomfortable truth: the research consistently shows it doesn't work very well, if at all.
Of nine studies directly examining whether docusate sodium effectively treats constipation, 89% concluded it does not. Major medical guidelines don't recommend it as a first-line treatment, and many hospitals are actively removing it from their formularies. So what should you actually use instead? This article breaks down what the research shows and what options are worth your time and money.
Cardiovascular HealthJun 4, 2026
If you're considering red yeast rice as a "natural" way to lower cholesterol, you've probably heard it's a gentler alternative to statin drugs. But research actually shows red yeast rice can cause the same side effects as statins, because it contains the same active ingredient. The good news? Serious problems are rare, and your risk depends heavily on the product you choose and the dose you take.
This article will help you understand what side effects to watch for, how often they actually occur, and what you can do to minimize your risk.
Cardiovascular HealthJun 4, 2026
Repatha (evolocumab), a PCSK9 inhibitor, has revolutionized lipid lowering by delivering dramatic reductions in low-density lipoprotein cholesterol (LDL-C). As its use expands across populations, understanding the dosing guidelines is crucial to ensure both safety and efficacy. Let’s dig into the clinical evidence supporting Repatha dosing recommendations, from adult use to familial hypercholesterolemia and pediatric populations.
